Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Illumina Settles BGI Patent Battles For $325M

Executive Summary

The settlement resolves a total of eight lawsuits between the companies on genetic sequencing technology and alleged antitrust violations.

You may also be interested in...



Jury Awards Nearly $334M To MGI Tech In Illumina Patent Suit

The jury said the infringement, which involved patents on two-channel sequencing chemistry technology, had been “willful” and turned down Illumina’s counterclaims. 

Eight Indicted In Alleged Genetic Testing Fraud

The eight had ties to a group of Tennessee labs that reportedly paid physicians to order medically unnecessary testing, billing Medicare more than $150m in five years.

Medtech Industry Mourns US Rep. Jackie Walorski

Indiana Republican Congresswoman Jackie Walorski, who died in a car crash Wednesday, was a strong proponent of device industry priorities such as device tax repeal and Medicare coverage for innovative technologies.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT145623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel